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Abstract 
Review on AURKB, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: AIK2, AIM-1, AIM1, ARK2, AurB, 
IPL1, PPP1R48, STK12, STK5, aurkb-sv1, aurkb-
sv2 
HGNC (Hugo): AURKB 
Location: 17p13.1 
DNA/RNA 
Description 
Aurora kinases are conserved during eukaryotic 
evolution. While the genomes of yeasts encode only 
one Aurora kinase (Ipl1 in budding yeast and Ark1 
in fission yeast), higher eukaryotes express two or 
more members of this family. In mammals, there 
are three members (Aurora A, B and C).  
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Schematic diagram of protein domains of Aurora B kinase and some key facts. DN -K106R marks the location of amino acid K at 
position 106 (ATP binding site), which will produce a dominant negative protein when K is mutated to R. T at position 232 is the 
phosphorylation site involved in autocatalysis. The A-Box and D-Box are consensus sequences for targeted polyubiquitination 
(King et al., 1996; Pfleger and Kirschner, 2000), and the A-Box in Aurora B is important for Aurora B degradation (Nguyen et al., 
2005). 
 
Aurora A (Aurora 2, ARK1, and BTAK) is present 
among all vertebrates. Aurora B (Aurora 1, ARK2, 
and AIM1) and Aurora-C (Aurora 3 and AIK3) 
came into existence from gene duplication during 
the evolution of mammals (Brown et al., 2004). 
Protein 
Description 
Size: 344 amino acids; molecular weight: 39.3 kDa. 
The AURKB gene has 8 exons, but there are 4 
isoforms of AURKB protein due to alternative 
splicing. 
The molecular structure of Aurora B has been 
determined by crystallography (Sessa et al., 2005; 
Andersen et al., 2008; Girdler et al., 2008). When 
the amino acid sequences of the ATP-binding 
pockets of Aurora A, B and C are compared, 3 of 
the 26 residues lining the active site in Aurora A, 
Leu215, Thr217 and R220, are different from the 
corresponding residues in Aurora B and C (Brown 
et al., 2004); there is no difference in these 26 
residues between Aurora B and C. The manner in 
which Aurora A binds to ATP (Bayliss et al., 2003) 
and ADP (Nowakowski et al., 2002) have been 
modeled. Because of the high degree of 
conservation of the active site between Aurora A 
and B, Aurora B is expected to interact with ATP 
and ADP in the same way as reported for Aurora A. 
INCENP interacts with AURKB at an α-helix 
domain and activates AURKB. AURKB-Sv1 lacks 
the INCENP interaction domain because part of 
exon 5 is missing and intron 5 and intron 6 may 
form a new domain. Therefore, the conformation of 
AURKB-Sv1 is expected to be different from 
AURKB, and the interaction with INCENP will be 
affected. 
In contrast, the α-helix domain for interacting with 
INCENP is intact in AURKB-Sv2, but AURKB-
Sv2 is missing major parts of the kinase domain. 
Thus, AURKB-Sv2 does not have kinase activity 
and may act as a dominant negative competitor 
against AURKB. 
Small molecule inhibitors target the ATP-binding 
pocket of aurora kinases.  
There are data available from the Protein Data Bank 
website (http://www.pdg.org) regarding the 
interaction of Aurora B with 3 inhibitors [AD6 (4-
[(5-bromo-1,3-thiazol-2-yl) amino]-N-
methylbenzamide): PDB ID 2vgp (Andersen et al., 
2008), ZM447439: PDB ID 2vrx (Girdler et al., 
2008), and hesperadin: PDB ID 2bfy (Sessa et al., 
2005)]. 
Expression 
The expression of Aurora kinases varies with cell 
cycle phases, being at very low levels in the non-M 
phases (Fu et al., 2007; Gautschi et al., 2008; 
Mountzios et al., 2008).  
Although Aurora A and Aurora B are 
phylogenetically related, they have different 
biological functions and distinct temporo-spatial 
subcellular localization in mammals.  
In prophase, Aurora A is at the centrosomes while 
Aurora B starts to appear in the nucleus (Carmena 
and Earnshaw, 2003).  
In metaphase, Aurora A is near the spindle poles on 
the microtubules ends while Aurora B is on the 
centromeric regions of chromosomes as a 
chromosomal passenger protein.  
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AURKB has 4 alternative splicing variants: the longest one (344 aa); AURKB-Sv1 (312 aa), which loses part of exon 5 but 
contains a fragment of intron 5 and intron 6 instead; AURKB-Sv2 (303 aa), which lacks exon 6; and the shortest form (142 aa), 
which loses more than the C-terminal half of the protein (López-Saavedra and Herrera, 2010). The serines and threonines are 
highlighted to demonstrate the alignment. Helix domains are highlighted in magenta. The active site is highlighted in red. The 
nucleotide binding region is indicated by the rectangle. 
 
 
 
The surface model of ZM447439 bound to Aurora B (amino acid 77-361) is rendered using the program PyMOL. ZM447439 (in 
stick molecular structure) is shown in the active site ATP-binding pocket of Aurora B (blue), and the 3 residues that differ 
between Aurora B and A are highlighted in cyan. INCENP-A (amino acid 798-840) in complex with Aurora B is hidden by coloring 
it black. 
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In anaphase, Aurora A is at the polar microtubules 
while Aurora B relocates from the centromeres to 
the spindle midzone (spindle equator) where the 
microtubules from opposite poles interdigitate 
(Keen and Taylor, 2004). In cytokinesis, Aurora B 
accumulates at the cleavage furrow before finally 
concentrating at the midbody. 
Localisation 
The protein level and kinase activity of Aurora B 
are tightly controlled according to the phase of the 
cell cycle and the stages in mitosis. It expression 
peaks at the G2-M transition, whereas its kinase 
activity and subcellular localization change quickly 
according to the stage of mitosis. In mitosis, Aurora 
B, Survivin, Borealin and INCENP form the 
chromosomal passenger complex (Knauer et al., 
2007). It is located at the chromosomes in prophase, 
the centromeres in prometaphase and metaphase, 
the central mitotic spindle in anaphase, and the 
cleavage furrow in cytokinesis (Adams et al., 
2001). Analysis of the dynamics of Aurora B 
showed that the association of Aurora B with 
centromeres is dynamic (Murata-Hori et al., 2002) 
but the association with spindle microtubules 
during anaphase is static. Aurora B is transported to 
the equatorial cell cortex by astral microtubules. 
Function 
In mitosis, the chromosomal passenger complex, 
composed of Aurora B, Survivin, Borealin and 
INCENP, controls chromosome alignment, histone 
modification, and cytokinesis (Knauer et al., 2007). 
Presence of this complex at the right place at the 
right time is the key to precise control of its 
enzymatic core, i.e., the Aurora B kinase (Vader et 
al., 2006). Although Aurora B Kinase is found in 
complexes that contain Borealin, it is not required 
for the mitotic phosphorylation of Borealin (Kaur et 
al., 2007). Thus far, there are a number of known 
substrates of Aurora B: the RNA methyltransferase 
NSUN2 (Sakita-Suto et al., 2007), Septin-1 (Qi et 
al., 2005), vimentin (Goto et al., 2003), histone H3 
(Sugiyama et al., 2002), MgcRacGAP (Minoshima 
et al., 2003), INCENP (Bishop and Schumacher, 
2002; Honda et al., 2003), Survivin (Wheatley et 
al., 2007) and TP53 (Gully et al., 2012). 
Aurora B activity is regulated in a variety of ways. 
It autophosphorylates at T232 through interaction 
with INCENP (Yasui et al., 2004). The 
phosphorylation of T232 is indispensable for its 
kinase activity. The temporo-spatial dynamics of 
Aurora B is determined by its binding to tubulin 
(Warner et al., 2006), regulation by other kinases 
and phosphatases (Sugiyama et al., 2002; 
Gruneberg et al., 2004), and proteasomal 
degradation after poly-ubiquitination (Nguyen et 
al., 2005; Stewart and Fang, 2005; Sumara et al., 
2007). Survivin (Chen et al., 2003) and protein 
serine/threonine phosphatase type 1 (PP1) or type 
2A (PP2A) (Sugiyama et al., 2002) regulate Aurora 
B kinase activation while MKlp2 controls Aurora B 
localization in anaphase (Gruneberg et al., 2004). 
Regarding mitotic chromosome condensation, 
Aurora B directly phosphorylates histone H3, not 
only at S10 but also at S28. The level of S28 
phosphorylation is rendered undetectable by PP1 
just prior to entry into mitosis (Goto et al., 2002). 
Aurora B binds three other chromosome passenger 
proteins - inner centromere protein (INCENP), 
Survivin and Borealin - to form a complex that 
targets Aurora B to both centromeres and the 
spindle. The assembly of the outer kinetochore, 
which binds microtubules to control chromosome 
movement, is restricted to mitosis, whereas the 
inner kinetochore remains tethered to the 
centromeres throughout the cell cycle. Aurora B 
and PP1 coordinate and mediate cell cycle-
dependent changes in kinetochore assembly by 
regulating the phosphorylation status of kinetochore 
substrates (Emanuele et al., 2008). The binding of 
mitotic checkpoint kinase Budding Uninhibited by 
Benzimidazoles1 beta (BubR1) to kinetochores is 
regulated by the survivin/Aurora B complex. 
Aurora B phosphorylates mitotic centromere-
associated kinesin (MCAK) at merotelic 
attachments and regulates the microtubule 
depolymerase activity of MCAK (Knowlton et al., 
2006). These functions of Aurora B are essential for 
proper chromosome segregation (Lens and 
Medema, 2003). Aurora B regulates the cleavage 
furrow-specific vimentin by phosphorylation and 
controls vimentin filament segregation in 
cytokinesis (Goto et al., 2003). 
Checkpoint kinase 1 (Chk1) is a component of the 
DNA damage checkpoint, and it augments spindle 
checkpoint signaling by activating Aurora B and 
BubR1 (Zachos et al., 2007). Aurora B kinase 
activity is also regulated by poly(ADP-
ribosyl)ation; activation of Poly [ADP-ribose] 
polymerase 1 (PARP1) in response to DNA damage 
will lead to a striking inhibition of Aurora B kinase 
activity by poly(ADP-ribosyl)ation (Monaco et al., 
2005). 
Homology 
Intriguingly, replacing the amino acid residue G198 
of Aurora A with the equivalent residue N142 of 
Aurora B, i.e., Aurora A (G198N), makes this 
single amino acid mutant behave like Aurora B (Fu 
et al., 2009). Aurora A (G198N) is localized in the 
inner centromere in metaphase and the midzone in 
anaphase just like Aurora B, and it can compensate 
for the loss of Aurora B in chromosome 
misalignment and premature exit from mitosis. It 
binds to and phosphorylates INCENP and Survivin. 
Therefore, the presence of glycine (G) or 
asparagines (N) at a single site assigns Aurora A-
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like or B-like functions and properties (Fu et al., 
2009). 
Implicated in 
Lung adenocarcinoma 
Note 
(Smith et al., 2005; Vischioni et al., 2006) 
Prognosis 
High Aurora B expression predicts short survival 
for lung adenocarcinoma (Vischioni et al., 2006). 
Oncogenesis 
High Aurora B expression correlates with cell 
proliferation, dedifferentiation, and metastasis in 
lung cancer patients (Vischioni et al., 2006). 
Acute myeloid leukemia 
Note 
(Ikezoe et al., 2007) 
Oncogenesis 
In an analysis comparing 44 samples of freshly 
isolated AML cells with 11 bone marrow 
mononuclear cells from healthy volunteers and 12 
peripheral blood mononuclear cells from healthy 
volunteers, measurement of relative mRNA 
expression of Aurora B shows that it is upregulated 
in the majority of cases (Ikezoe et al., 2007). In 
high-risk myelodysplastic syndrome and secondary 
AML, surviving and aurora B are expressed in high 
levels in the CD34+ cells (Yoshida et al., 2012). 
Aurora B overexpression may have contributed to 
genomic instability and progression from 
myelodysplastic syndrome to AML. 
Prostate cancer 
Note 
(Ditchfield et al., 2003; Chieffi et al., 2006) 
Oncogenesis 
Aurora B expression correlates with prostate cancer 
cell proliferation (Chieffi et al., 2006). 
Anaplastic thyroid carcinomas 
Note 
(Sorrentino et al., 2005) 
Oncogenesis 
Aurora B overexpression promotes thyroid 
carcinoma cell proliferation and is associated with 
undifferentiated thyroid cancer (Sorrentino et al., 
2005). 
Hepatocellular carcinoma 
Note 
(Sistayanarain et al., 2006) 
Prognosis 
High Aurora B expression predicts short survival 
for hepatocellular carcinoma (Tanaka et al., 2008).  
Yasen et al. (Yasen et al., 2009) studied the 
expression of the isoforms of Aurora B in 10 HCC 
cell lines and 253 samples from patients with 
varying degrees of HCC malignancy.  
AURKB was aberrantly expressed in HCC cell 
lines and primary HCC tumors. 
Abnormal protein 
Expression of AURKB-Sv2 is associated with 
advanced stages of HCC, high levels of α-
fetoprotein, tumor invasion, multiple tumor 
formation, and shortened disease-free survival 
(Yasen et al., 2009).  
AURKB-Sv2 may be a marker of poor prognosis. 
Oncogenesis 
Cell cycle phase-inappropriate phosphorylation of 
histone H3 in the entire cell cycle may enhance 
proliferation of liver cancer cells (Sistayanarain et 
al., 2006). 
Glioblastoma multiforme 
Note 
(Zeng et al., 2007) 
Prognosis 
High Aurora B expression predicts short survival 
for glioblastoma multiforme (Zeng et al., 2007). 
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